GREY:IPCIQ - Post by User
Post by
Nogah3on Jan 16, 2020 1:36am
247 Views
Post# 30558905
Pipeline
Pipeline Hi all,
Lots of chatter about what typically goes on with companies like this. To provide some clarity, I think we need to look at the real reason that drove the company's resurgence over the last month.
IPCI already has 6 FDA approved drugs (with one other pending approval). The US Market size for these is $2.44 Billion. Recently, Exclusive Licence and Commercial Supply agreements were signed with Tris Pharma for Quetiapine (Aug 15), Desvenlafaxine (Sep 5), and Velafaxine (Nov 25). These signings reach the same market size as Oxycodone ($1.3 Bil). So the stock price explosion from $0.20 to $1.20 is appropriate. Why? Because revenue is about to get a boost in Q4, even without Oxycodone.
And let's not forget a few things:
(1) the company also has the FDA approved Dexmethylphenidate (ADHD drug) already producing revenue
(2) there are two other FDA approved drugs (Metformin for diabetes and Levetiracetam for seizures) yet to be licenced out for additional revenue
(3) there are five other drugs in the works (excluding Oxycodone) that together have a market size of $7.63 Bil.
(4) Oxycodone ER can still be approved by FDA at a later date once the company provides evidence that it is unlikely to be abused by snorting
Given the recent signings and great potential, I am not surprised that this company's projected 1 year price target exceeds $10.
Anyhow, I hope this sheds light on things, and helps you make an informed decision.
source: https://www.intellipharmaceutics.com/product-pipeline
-----------------------------------------------------------------------------------------